Abstract

CCSG Developmental Funds provide a key source of support for the strategic and programmatic priorities and scientific opportunities of Wake Forest Baptist Comprehensive Cancer Center (WFBCCC), as identified through Planning and Evaluation processes. These funds provide opportunities to explore innovative pilot projects, new collaborations, and new technologies. In the current funding period, Developmental Funds have been used for the purposes of 1) pilot funds and 2) Shared Resource development. The WFBCCC proposes to continue funding in these two categories in the next funding cycle. It will also fund one Research Staff Investigator with Developmental Funds, in accordance with the new CCSG guidelines. Previously, Research Staff Investigators were supported by a separate CCSG budget category, not as a part of Developmental Funds. Using CCSG Developmental Funds, the WFBCCC supported 21 pilot projects in the amount of $657,900 between 2011 and 2015. The WFBCCC realized a 13.5 fold return on investment for CCSG-supported pilots, excluding the pilots from 2015, which have not yet had time to yield a return.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA012197-42
Application #
9209684
Study Section
Special Emphasis Panel (NCI (K1)-A)
Project Start
Project End
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
42
Fiscal Year
2017
Total Cost
$417,556
Indirect Cost
$148,165

  Institution

Name
Wake Forest University Health Sciences
Department
Type
Domestic Higher Education
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157

  Publications

Yang, M; Forbes, M E; Bitting, R L et al. (2018) Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? Ann Oncol 29:311-323
Godwin, Ryan C; Gmeiner, William H; Salsbury Jr, Freddie R (2018) All-atom molecular dynamics comparison of disease-associated zinc fingers. J Biomol Struct Dyn 36:2581-2594
Lamar, Zanetta S; Dothard, Andrew; Kennedy, LeAnne et al. (2018) Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leuk Lymphoma 59:1871-1877
Votanopoulos, Konstantinos Ioannis; Bartlett, David; Moran, Brendan et al. (2018) PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries. Ann Surg Oncol 25:674-678
Bhatt, Nikunj B; Pandya, Darpan N; Dezarn, William A et al. (2018) Practical Guidelines for Cerenkov Luminescence Imaging with Clinically Relevant Isotopes. Methods Mol Biol 1790:197-208
Melvin, Ryan L; Xiao, Jiajie; Berenhaut, Kenneth S et al. (2018) Using correlated motions to determine sufficient sampling times for molecular dynamics. Phys Rev E 98:023307
Mao, Chengqiong; Qu, Ping; Miley, Michael J et al. (2018) P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates. Biomater Sci 6:3063-3074
Gesell, Sabina B; Golden, Shannon L; Limkakeng Jr, Alexander T et al. (2018) Implementation of the HEART Pathway: Using the Consolidated Framework for Implementation Research. Crit Pathw Cardiol 17:191-200
Andrews, Rachel N; Caudell, David L; Metheny-Barlow, Linda J et al. (2018) Fibronectin Produced by Cerebral Endothelial and Vascular Smooth Muscle Cells Contributes to Perivascular Extracellular Matrix in Late-Delayed Radiation-Induced Brain Injury. Radiat Res 190:361-373
Bhatt, Nikunj B; Pandya, Darpan N; Rideout-Danner, Stephanie et al. (2018) A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents. Dalton Trans 47:13214-13221

Showing the most recent 10 out of 548 publications